• +91 9169164321 (Asia)
  • +1(646)-781-7170 (Int'l)
  • help@24lifesciences.com
Cart (0)

COVID-19 Impact on Global Neuroendocrine Tumor Treatment Market Size, Status and Forecast 2020-2026

report cover
  • 22 June 2020
  • Pharmaceuticals
  • 90 Pages
  • Report Code: 24LS-8623
  • Formate :   
Download FREE Report Sample Download PDF File

COVID 19 Impact Neuroendocrine Tumor Treatment -MARKET ADVISORY SERVICES

This report focuses on the global Neuroendocrine Tumor Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Neuroendocrine Tumor Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
Exelixis, Inc.
Advanced Accelerator Applications
Dauntless Pharmaceuticals, Inc.
Hutchinson Medipharma Limited
Ispen
Novartis AG
Progenics Pharmaceuticals, Inc.
Tarveda Therapeutics

Market segment by Type, the product can be split into
Everolimus
Sunitinib
Lu-Dotatate
Lanreotide
Octreotide
Market segment by Application, split into
Hospitals
Clinic
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Neuroendocrine Tumor Treatment status, future forecast, growth opportunity, key market and key players.
To present the Neuroendocrine Tumor Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Neuroendocrine Tumor Treatment are as follows:
History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Neuroendocrine Tumor Treatment Revenue
1.4 Market Analysis by Type
1.4.1 Global Neuroendocrine Tumor Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Everolimus
1.4.3 Sunitinib
1.4.4 Lu-Dotatate
1.4.5 Lanreotide
1.4.6 Octreotide
1.5 Market by Application
1.5.1 Global Neuroendocrine Tumor Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinic
1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Neuroendocrine Tumor Treatment Industry Impact
1.6.1 How the Covid-19 is Affecting the Neuroendocrine Tumor Treatment Industry
1.6.1.1 Neuroendocrine Tumor Treatment Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Neuroendocrine Tumor Treatment Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Neuroendocrine Tumor Treatment Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 Global Growth Trends by Regions
2.1 Neuroendocrine Tumor Treatment Market Perspective (2015-2026)
2.2 Neuroendocrine Tumor Treatment Growth Trends by Regions
2.2.1 Neuroendocrine Tumor Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Neuroendocrine Tumor Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Neuroendocrine Tumor Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Neuroendocrine Tumor Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Neuroendocrine Tumor Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Neuroendocrine Tumor Treatment Players by Market Size
3.1.1 Global Top Neuroendocrine Tumor Treatment Players by Revenue (2015-2020)
3.1.2 Global Neuroendocrine Tumor Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Neuroendocrine Tumor Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Neuroendocrine Tumor Treatment Market Concentration Ratio
3.2.1 Global Neuroendocrine Tumor Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Neuroendocrine Tumor Treatment Revenue in 2019
3.3 Neuroendocrine Tumor Treatment Key Players Head office and Area Served
3.4 Key Players Neuroendocrine Tumor Treatment Product Solution and Service
3.5 Date of Enter into Neuroendocrine Tumor Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)
4.1 Global Neuroendocrine Tumor Treatment Historic Market Size by Type (2015-2020)
4.2 Global Neuroendocrine Tumor Treatment Forecasted Market Size by Type (2021-2026)

5 Neuroendocrine Tumor Treatment Breakdown Data by Application (2015-2026)
5.1 Global Neuroendocrine Tumor Treatment Market Size by Application (2015-2020)
5.2 Global Neuroendocrine Tumor Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Neuroendocrine Tumor Treatment Market Size (2015-2020)
6.2 Neuroendocrine Tumor Treatment Key Players in North America (2019-2020)
6.3 North America Neuroendocrine Tumor Treatment Market Size by Type (2015-2020)
6.4 North America Neuroendocrine Tumor Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Neuroendocrine Tumor Treatment Market Size (2015-2020)
7.2 Neuroendocrine Tumor Treatment Key Players in Europe (2019-2020)
7.3 Europe Neuroendocrine Tumor Treatment Market Size by Type (2015-2020)
7.4 Europe Neuroendocrine Tumor Treatment Market Size by Application (2015-2020)

8 China
8.1 China Neuroendocrine Tumor Treatment Market Size (2015-2020)
8.2 Neuroendocrine Tumor Treatment Key Players in China (2019-2020)
8.3 China Neuroendocrine Tumor Treatment Market Size by Type (2015-2020)
8.4 China Neuroendocrine Tumor Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Neuroendocrine Tumor Treatment Market Size (2015-2020)
9.2 Neuroendocrine Tumor Treatment Key Players in Japan (2019-2020)
9.3 Japan Neuroendocrine Tumor Treatment Market Size by Type (2015-2020)
9.4 Japan Neuroendocrine Tumor Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Neuroendocrine Tumor Treatment Market Size (2015-2020)
10.2 Neuroendocrine Tumor Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Neuroendocrine Tumor Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Neuroendocrine Tumor Treatment Market Size by Application (2015-2020)

11 India
11.1 India Neuroendocrine Tumor Treatment Market Size (2015-2020)
11.2 Neuroendocrine Tumor Treatment Key Players in India (2019-2020)
11.3 India Neuroendocrine Tumor Treatment Market Size by Type (2015-2020)
11.4 India Neuroendocrine Tumor Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Neuroendocrine Tumor Treatment Market Size (2015-2020)
12.2 Neuroendocrine Tumor Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Neuroendocrine Tumor Treatment Market Size by Type (2015-2020)
12.4 Central & South America Neuroendocrine Tumor Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Exelixis, Inc.
13.1.1 Exelixis, Inc. Company Details
13.1.2 Exelixis, Inc. Business Overview and Its Total Revenue
13.1.3 Exelixis, Inc. Neuroendocrine Tumor Treatment Introduction
13.1.4 Exelixis, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2015-2020))
13.1.5 Exelixis, Inc. Recent Development
13.2 Advanced Accelerator Applications
13.2.1 Advanced Accelerator Applications Company Details
13.2.2 Advanced Accelerator Applications Business Overview and Its Total Revenue
13.2.3 Advanced Accelerator Applications Neuroendocrine Tumor Treatment Introduction
13.2.4 Advanced Accelerator Applications Revenue in Neuroendocrine Tumor Treatment Business (2015-2020)
13.2.5 Advanced Accelerator Applications Recent Development
13.3 Dauntless Pharmaceuticals, Inc.
13.3.1 Dauntless Pharmaceuticals, Inc. Company Details
13.3.2 Dauntless Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.3.3 Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Introduction
13.3.4 Dauntless Pharmaceuticals, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2015-2020)
13.3.5 Dauntless Pharmaceuticals, Inc. Recent Development
13.4 Hutchinson Medipharma Limited
13.4.1 Hutchinson Medipharma Limited Company Details
13.4.2 Hutchinson Medipharma Limited Business Overview and Its Total Revenue
13.4.3 Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Introduction
13.4.4 Hutchinson Medipharma Limited Revenue in Neuroendocrine Tumor Treatment Business (2015-2020)
13.4.5 Hutchinson Medipharma Limited Recent Development
13.5 Ispen
13.5.1 Ispen Company Details
13.5.2 Ispen Business Overview and Its Total Revenue
13.5.3 Ispen Neuroendocrine Tumor Treatment Introduction
13.5.4 Ispen Revenue in Neuroendocrine Tumor Treatment Business (2015-2020)
13.5.5 Ispen Recent Development
13.6 Novartis AG
13.6.1 Novartis AG Company Details
13.6.2 Novartis AG Business Overview and Its Total Revenue
13.6.3 Novartis AG Neuroendocrine Tumor Treatment Introduction
13.6.4 Novartis AG Revenue in Neuroendocrine Tumor Treatment Business (2015-2020)
13.6.5 Novartis AG Recent Development
13.7 Progenics Pharmaceuticals, Inc.
13.7.1 Progenics Pharmaceuticals, Inc. Company Details
13.7.2 Progenics Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.7.3 Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Introduction
13.7.4 Progenics Pharmaceuticals, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2015-2020)
13.7.5 Progenics Pharmaceuticals, Inc. Recent Development
13.8 Tarveda Therapeutics
13.8.1 Tarveda Therapeutics Company Details
13.8.2 Tarveda Therapeutics Business Overview and Its Total Revenue
13.8.3 Tarveda Therapeutics Neuroendocrine Tumor Treatment Introduction
13.8.4 Tarveda Therapeutics Revenue in Neuroendocrine Tumor Treatment Business (2015-2020)
13.8.5 Tarveda Therapeutics Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
List of Tables

Table 1. Neuroendocrine Tumor Treatment Key Market Segments

Table 2. Key Players Covered: Ranking by Neuroendocrine Tumor Treatment Revenue

Table 3. Ranking of Global Top Neuroendocrine Tumor Treatment Manufacturers by Revenue (US$ Million) in 2019

Table 4. Global Neuroendocrine Tumor Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026

Table 5. Key Players of Everolimus

Table 6. Key Players of Sunitinib

Table 7. Key Players of Lu-Dotatate

Table 8. Key Players of Lanreotide

Table 9. Key Players of Octreotide

Table 10. COVID-19 Impact Global Market: (Four Neuroendocrine Tumor Treatment Market Size Forecast Scenarios)

Table 11. Opportunities and Trends for Neuroendocrine Tumor Treatment Players in the COVID-19 Landscape

Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 13. Key Regions/Countries Measures against Covid-19 Impact

Table 14. Proposal for Neuroendocrine Tumor Treatment Players to Combat Covid-19 Impact

Table 15. Global Neuroendocrine Tumor Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026

Table 16. Global Neuroendocrine Tumor Treatment Market Size by Regions (US$ Million): 2020 VS 2026

Table 17. Global Neuroendocrine Tumor Treatment Market Size by Regions (2015-2020) (US$ Million)

Table 18. Global Neuroendocrine Tumor Treatment Market Share by Regions (2015-2020)

Table 19. Global Neuroendocrine Tumor Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)

Table 20. Global Neuroendocrine Tumor Treatment Market Share by Regions (2021-2026)

Table 21. Market Top Trends

Table 22. Key Drivers: Impact Analysis

Table 23. Key Challenges

Table 24. Neuroendocrine Tumor Treatment Market Growth Strategy

Table 25. Main Points Interviewed from Key Neuroendocrine Tumor Treatment Players

Table 26. Global Neuroendocrine Tumor Treatment Revenue by Players (2015-2020) (Million US$)

Table 27. Global Neuroendocrine Tumor Treatment Market Share by Players (2015-2020)

Table 28. Global Top Neuroendocrine Tumor Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Tumor Treatment as of 2019)

Table 29. Global Neuroendocrine Tumor Treatment by Players Market Concentration Ratio (CR5 and HHI)

Table 30. Key Players Headquarters and Area Served

Table 31. Key Players Neuroendocrine Tumor Treatment Product Solution and Service

Table 32. Date of Enter into Neuroendocrine Tumor Treatment Market

Table 33. Mergers & Acquisitions, Expansion Plans

Table 34. Global Neuroendocrine Tumor Treatment Market Size by Type (2015-2020) (Million US$)

Table 35. Global Neuroendocrine Tumor Treatment Market Size Share by Type (2015-2020)

Table 36. Global Neuroendocrine Tumor Treatment Revenue Market Share by Type (2021-2026)

Table 37. Global Neuroendocrine Tumor Treatment Market Size Share by Application (2015-2020)

Table 38. Global Neuroendocrine Tumor Treatment Market Size by Application (2015-2020) (Million US$)

Table 39. Global Neuroendocrine Tumor Treatment Market Size Share by Application (2021-2026)

Table 40. North America Key Players Neuroendocrine Tumor Treatment Revenue (2019-2020) (Million US$)

Table 41. North America Key Players Neuroendocrine Tumor Treatment Market Share (2019-2020)

Table 42. North America Neuroendocrine Tumor Treatment Market Size by Type (2015-2020) (Million US$)

Table 43. North America Neuroendocrine Tumor Treatment Market Share by Type (2015-2020)

Table 44. North America Neuroendocrine Tumor Treatment Market Size by Application (2015-2020) (Million US$)

Table 45. North America Neuroendocrine Tumor Treatment Market Share by Application (2015-2020)

Table 46. Europe Key Players Neuroendocrine Tumor Treatment Revenue (2019-2020) (Million US$)

Table 47. Europe Key Players Neuroendocrine Tumor Treatment Market Share (2019-2020)

Table 48. Europe Neuroendocrine Tumor Treatment Market Size by Type (2015-2020) (Million US$)

Table 49. Europe Neuroendocrine Tumor Treatment Market Share by Type (2015-2020)

Table 50. Europe Neuroendocrine Tumor Treatment Market Size by Application (2015-2020) (Million US$)

Table 51. Europe Neuroendocrine Tumor Treatment Market Share by Application (2015-2020)

Table 52. China Key Players Neuroendocrine Tumor Treatment Revenue (2019-2020) (Million US$)

Table 53. China Key Players Neuroendocrine Tumor Treatment Market Share (2019-2020)

Table 54. China Neuroendocrine Tumor Treatment Market Size by Type (2015-2020) (Million US$)

Table 55. China Neuroendocrine Tumor Treatment Market Share by Type (2015-2020)

Table 56. China Neuroendocrine Tumor Treatment Market Size by Application (2015-2020) (Million US$)

Table 57. China Neuroendocrine Tumor Treatment Market Share by Application (2015-2020)

Table 58. Japan Key Players Neuroendocrine Tumor Treatment Revenue (2019-2020) (Million US$)

Table 59. Japan Key Players Neuroendocrine Tumor Treatment Market Share (2019-2020)

Table 60. Japan Neuroendocrine Tumor Treatment Market Size by Type (2015-2020) (Million US$)

Table 61. Japan Neuroendocrine Tumor Treatment Market Share by Type (2015-2020)

Table 62. Japan Neuroendocrine Tumor Treatment Market Size by Application (2015-2020) (Million US$)

Table 63. Japan Neuroendocrine Tumor Treatment Market Share by Application (2015-2020)

Table 64. Southeast Asia Key Players Neuroendocrine Tumor Treatment Revenue (2019-2020) (Million US$)

Table 65. Southeast Asia Key Players Neuroendocrine Tumor Treatment Market Share (2019-2020)

Table 66. Southeast Asia Neuroendocrine Tumor Treatment Market Size by Type (2015-2020) (Million US$)

Table 67. Southeast Asia Neuroendocrine Tumor Treatment Market Share by Type (2015-2020)

Table 68. Southeast Asia Neuroendocrine Tumor Treatment Market Size by Application (2015-2020) (Million US$)

Table 69. Southeast Asia Neuroendocrine Tumor Treatment Market Share by Application (2015-2020)

Table 70. India Key Players Neuroendocrine Tumor Treatment Revenue (2019-2020) (Million US$)

Table 71. India Key Players Neuroendocrine Tumor Treatment Market Share (2019-2020)

Table 72. India Neuroendocrine Tumor Treatment Market Size by Type (2015-2020) (Million US$)

Table 73. India Neuroendocrine Tumor Treatment Market Share by Type (2015-2020)

Table 74. India Neuroendocrine Tumor Treatment Market Size by Application (2015-2020) (Million US$)

Table 75. India Neuroendocrine Tumor Treatment Market Share by Application (2015-2020)

Table 76. Central & South America Key Players Neuroendocrine Tumor Treatment Revenue (2019-2020) (Million US$)

Table 77. Central & South America Key Players Neuroendocrine Tumor Treatment Market Share (2019-2020)

Table 78. Central & South America Neuroendocrine Tumor Treatment Market Size by Type (2015-2020) (Million US$)

Table 79. Central & South America Neuroendocrine Tumor Treatment Market Share by Type (2015-2020)

Table 80. Central & South America Neuroendocrine Tumor Treatment Market Size by Application (2015-2020) (Million US$)

Table 81. Central & South America Neuroendocrine Tumor Treatment Market Share by Application (2015-2020)

Table 82. Exelixis, Inc. Company Details

Table 83. Exelixis, Inc. Business Overview

Table 84. Exelixis, Inc. Product

Table 85. Exelixis, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2015-2020) (Million US$)

Table 86. Exelixis, Inc. Recent Development

Table 87. Advanced Accelerator Applications Company Details

Table 88. Advanced Accelerator Applications Business Overview

Table 89. Advanced Accelerator Applications Product

Table 90. Advanced Accelerator Applications Revenue in Neuroendocrine Tumor Treatment Business (2015-2020) (Million US$)

Table 91. Advanced Accelerator Applications Recent Development

Table 92. Dauntless Pharmaceuticals, Inc. Company Details

Table 93. Dauntless Pharmaceuticals, Inc. Business Overview

Table 94. Dauntless Pharmaceuticals, Inc. Product

Table 95. Dauntless Pharmaceuticals, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2015-2020) (Million US$)

Table 96. Dauntless Pharmaceuticals, Inc. Recent Development

Table 97. Hutchinson Medipharma Limited Company Details

Table 98. Hutchinson Medipharma Limited Business Overview

Table 99. Hutchinson Medipharma Limited Product

Table 100. Hutchinson Medipharma Limited Revenue in Neuroendocrine Tumor Treatment Business (2015-2020) (Million US$)

Table 101. Hutchinson Medipharma Limited Recent Development

Table 102. Ispen Company Details

Table 103. Ispen Business Overview

Table 104. Ispen Product

Table 105. Ispen Revenue in Neuroendocrine Tumor Treatment Business (2015-2020) (Million US$)

Table 106. Ispen Recent Development

Table 107. Novartis AG Company Details

Table 108. Novartis AG Business Overview

Table 109. Novartis AG Product

Table 110. Novartis AG Revenue in Neuroendocrine Tumor Treatment Business (2015-2020) (Million US$)

Table 111. Novartis AG Recent Development

Table 112. Progenics Pharmaceuticals, Inc. Company Details

Table 113. Progenics Pharmaceuticals, Inc. Business Overview

Table 114. Progenics Pharmaceuticals, Inc. Product

Table 115. Progenics Pharmaceuticals, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2015-2020) (Million US$)

Table 116. Progenics Pharmaceuticals, Inc. Recent Development

Table 117. Tarveda Therapeutics Business Overview

Table 118. Tarveda Therapeutics Product

Table 119. Tarveda Therapeutics Company Details

Table 120. Tarveda Therapeutics Revenue in Neuroendocrine Tumor Treatment Business (2015-2020) (Million US$)

Table 121. Tarveda Therapeutics Recent Development

Table 122. Research Programs/Design for This Report

Table 123. Key Data Information from Secondary Sources

Table 124. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Neuroendocrine Tumor Treatment Market Share by Type: 2020 VS 2026

Figure 2. Everolimus Features

Figure 3. Sunitinib Features

Figure 4. Lu-Dotatate Features

Figure 5. Lanreotide Features

Figure 6. Octreotide Features

Figure 7. Global Neuroendocrine Tumor Treatment Market Share by Application: 2020 VS 2026

Figure 8. Hospitals Case Studies

Figure 9. Clinic Case Studies

Figure 10. Others Case Studies

Figure 11. Neuroendocrine Tumor Treatment Report Years Considered

Figure 12. Global Neuroendocrine Tumor Treatment Market Size YoY Growth 2015-2026 (US$ Million)

Figure 13. Global Neuroendocrine Tumor Treatment Market Share by Regions: 2020 VS 2026

Figure 14. Global Neuroendocrine Tumor Treatment Market Share by Regions (2021-2026)

Figure 15. Porter's Five Forces Analysis

Figure 16. Global Neuroendocrine Tumor Treatment Market Share by Players in 2019

Figure 17. Global Top Neuroendocrine Tumor Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Tumor Treatment as of 2019

Figure 18. The Top 10 and 5 Players Market Share by Neuroendocrine Tumor Treatment Revenue in 2019

Figure 19. North America Neuroendocrine Tumor Treatment Market Size YoY Growth (2015-2020) (Million US$)

Figure 20. Europe Neuroendocrine Tumor Treatment Market Size YoY Growth (2015-2020) (Million US$)

Figure 21. China Neuroendocrine Tumor Treatment Market Size YoY Growth (2015-2020) (Million US$)

Figure 22. Japan Neuroendocrine Tumor Treatment Market Size YoY Growth (2015-2020) (Million US$)

Figure 23. Southeast Asia Neuroendocrine Tumor Treatment Market Size YoY Growth (2015-2020) (Million US$)

Figure 24. India Neuroendocrine Tumor Treatment Market Size YoY Growth (2015-2020) (Million US$)

Figure 25. Central & South America Neuroendocrine Tumor Treatment Market Size YoY Growth (2015-2020) (Million US$)

Figure 26. Exelixis, Inc. Total Revenue (US$ Million): 2019 Compared with 2018

Figure 27. Exelixis, Inc. Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2015-2020)

Figure 28. Advanced Accelerator Applications Total Revenue (US$ Million): 2019 Compared with 2018

Figure 29. Advanced Accelerator Applications Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2015-2020)

Figure 30. Dauntless Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018

Figure 31. Dauntless Pharmaceuticals, Inc. Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2015-2020)

Figure 32. Hutchinson Medipharma Limited Total Revenue (US$ Million): 2019 Compared with 2018

Figure 33. Hutchinson Medipharma Limited Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2015-2020)

Figure 34. Ispen Total Revenue (US$ Million): 2019 Compared with 2018

Figure 35. Ispen Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2015-2020)

Figure 36. Novartis AG Total Revenue (US$ Million): 2019 Compared with 2018

Figure 37. Novartis AG Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2015-2020)

Figure 38. Progenics Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018

Figure 39. Progenics Pharmaceuticals, Inc. Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2015-2020)

Figure 40. Tarveda Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018

Figure 41. Tarveda Therapeutics Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2015-2020)

Figure 42. Bottom-up and Top-down Approaches for This Report

Figure 43. Data Triangulation

Figure 44. Key Executives Interviewed

Exelixis, Inc.

Advanced Accelerator Applications

Dauntless Pharmaceuticals, Inc.

Hutchinson Medipharma Limited

Ispen

Novartis AG

Progenics Pharmaceuticals, Inc.

Tarveda Therapeutics

CHOOSE YOUR BUYING OPTION COVID-19 Revised Pricing Of the Month

SECURITY ASSUREDpayment image

Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

CHECK TODAYS BEST PRICE

BEST PRICE: $3120

SOME OF OUR CLIENTS

OUR KEY POINTS

  • Comprehensive Research

    Offers Penetrative insights & holistic understanding of the market

  • Data Accuracy & Reliability

    Strictly follows the Research Meth-odology for flawless results

  • Competitive Pricing

    Ensure the best and affordable pricing

  • Security & Confidentiality

    All your transactions are secured end-to-end, ensuring a satisfactory purchase